HAEMONETICS CORP

HAE

HAEMONETICS CORP

HAE

Insider Sentiment (TTM):

Last Purchase:2025-11-10Last Sale:2024-07-26Shares Purchased (TTM):1,400Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:45,448,704Shares Outstanding:47,179,000Institutional Ownership Pct.:96.33%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	223	245	363	296	293	307	321	299	344	179	194	351
Accounts Receivable Net Current	216	217	196	207	201	203	212	214	201	207	212	174
Inventory Net	307	306	321	336	361	365	360	382	374	317	304	286
Prepaid Expense And Other Assets Current	65	66	63	60	59	60	113	61	59	66	55	55
Assets Current	811	835	944	900	913	935	1,006	956	979	769	765	866
Property Plant And Equipment Net	304	306	297	292	287	284	286	300	302	311	319	308
Intangible Assets Net Excluding Goodwill	435	448	420	428	451	456	466	488	495	406	429	251
Goodwill	657	656	607	606	607	604	605	616	613	565	555	465
Deferred Income Tax Assets Net	9	10	7	8	8	8	8	9	9	8	5	5
Other Assets Noncurrent	150	142	216	208	196	164	160	156	142	136	127	117
Assets	2,365	2,396	2,491	2,442	2,462	2,451	2,531	2,525	2,541	2,196	2,200	2,011
Liabilities And Stockhold…
Liabilities Current
Long Term Debt Current	5	5	305	304	304	304	5	5	5	10	14	14
Accounts Payable Current	56	51	49	62	46	67	63	69	77	73	57	80
Employee Related Liabilities Current	38	68	52	48	36	59	46	49	41	81	59	46
Other Liabilities Current	164	158	134	134	146	148	139	150	137	136	132	125
Liabilities Current	263	283	540	548	531	578	253	274	260	300	262	264
Long Term Debt Noncurrent	1,169	1,220	920	920	921	921	1,220	1,220	1,218	798	857	749
Deferred Income Tax Liabilities Net	39	38	56	58	59	63	61	63	65	63	62	35
Other Liabilities Noncurrent	57	59	64	66	68	68	90	90	92	75	76	70
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	1	1	1	1	1	1
Additional Paid In Capital Common Stock	567	554	565	553	562	523	570	544	561	635	627	617
Retained Earnings Accumulated Deficit	312	279	381	336	356	352	392	369	387	360	340	309
Accumulated Other Comprehensive Income Loss Net Of…	-42	-38	-35	-41	-36	-55	-56	-35	-43	-36	-24	-33
Stockholders Equity	837	796	911	849	882	821	907	879	905	960	943	894
Liabilities And Stockholders Equity	2,365	2,396	2,491	2,442	2,462	2,451	2,531	2,525	2,541	2,196	2,200	2,011
Allowance For Doubtful Accounts Receivable Current	4	4	4	6	6	6	6	6	6	6	6	5
Finite Lived Intangible Assets Accumulated Amortiz…	375	364	352	340	331	316	312	485	470	455	443	433
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	45	45	47	47	48	48	50	50	51	51	51	51
Shares Outstanding	45	45	47	47	48	48	50	50	51	51	51	51

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2027	-	-	-	-	-	-	-	-	-	-	-	-
2026	-1.96%	-13.41%	-7.86%	21.22%	19.62%	2.55%	-2.61%	-16.89%	-7.83%	31.30%	27.92%	-
2025	-1.11%	4.41%	-1.14%	1.09%	-10.35%	-18.16%	3.98%	0.32%	-0.76%	4.74%	12.85%	-19.32%
2024	0.33%	-0.40%	-5.99%	-4.12%	2.97%	-1.76%	-5.06%	9.27%	16.49%	-11.14%	-4.92%	-19.15%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.08	2.95	1.75	1.64	1.72	1.62	3.97	3.49	3.76	2.56	2.92	3.28
Quick Ratio	1.67	1.64	1.04	0.92	0.93	0.88	2.10	1.87	2.10	1.28	1.55	1.99
Working Capital	547.60M	552.28M	403.81M	351.36M	381.75M	356.86M	752.64M	681.96M	718.50M	468.52M	503.23M	601.53M
Leverage & Debt
Debt to Equity	0.31	0.35	0.59	0.65	0.60	0.70	0.28	0.31	0.29	0.31	0.28	0.30
Debt Ratio	0.11	0.12	0.22	0.22	0.22	0.24	0.10	0.11	0.10	0.14	0.12	0.13
Efficiency & Turnover
Asset Turnover TTM	0.42	0.41	0.39	0.40	0.41	0.44	0.44	0.45	0.44	0.47	0.47	0.48
Days Sales Outstanding TTM	75.64	77.52	75.33	76.97	72.29	72.49	75.03	69.52	69.75	72.89	74.21	67.51
Receivables Turnover TTM	4.83	4.71	4.85	4.74	5.05	5.04	4.86	5.25	5.23	5.01	4.92	5.41
Per Share Metrics
Diluted EPS TTM	2.11	2.05	3.73	3.53	3.38	3.31	2.57	2.42	2.23	2.29	2.46	2.50
Free Cash Flow Per Share TTM	6.72	3.05	4.10	2.94	1.23	2.83	1.97	0.95	1.95	2.83	3.03	4.27
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	79.37%	79.74%	79.22%	77.57%	75.46%	72.70%	71.03%	70.35%	70.58%	71.61%	69.57%	69.82%
Operating Profit Margin TTM	15.94%	15.87%	25.42%	24.34%	23.23%	21.53%	17.51%	16.44%	15.24%	17.07%	17.62%	17.92%
Net Profit Margin TTM	9.57%	9.85%	17.76%	16.87%	16.09%	16.28%	12.62%	12.16%	11.60%	12.17%	13.11%	13.72%
Growth Metrics
Net Revenue Growth (1Y)	-0.96%	-4.13%	-4.13%	-2.03%	2.51%	6.67%	6.67%	8.89%	8.37%	11.75%	11.75%	14.18%
Net Income Growth (1Y)	-41.05%	-41.97%	34.88%	35.84%	42.17%	42.64%	2.76%	-3.48%	-15.87%	1.87%	32.18%	49.08%
EPS Growth (1Y)	-37.48%	-38.09%	44.96%	45.29%	50.54%	43.70%	3.74%	-3.81%	-16.54%	2.02%	31.51%	49.74%
Valuation Metrics
P/E TTM	35.33	27.33	21.38	13.79	21.98	19.07	30.19	33.04	36.68	36.81	34.30	35.42
P/B TTM	4.06	3.34	4.11	2.73	4.07	3.90	4.33	4.66	4.66	4.51	4.60	5.08
P/S TTM	3.38	2.69	3.80	2.33	3.53	3.10	3.81	4.02	4.25	4.48	4.50	4.86
Market Cap	3.40B	2.66B	3.75B	2.32B	3.59B	3.20B	3.93B	4.09B	4.21B	4.33B	4.34B	4.54B
Enterprise Value	4.35B	3.64B	4.61B	3.25B	4.52B	4.12B	4.83B	5.02B	5.09B	4.96B	5.02B	4.96B
Calculated Values
Free Cash Flow TTM	304.86M	144.10M	191.74M	139.74M	59.19M	142.45M	98.93M	48.52M	99.14M	143.63M	153.92M	216.68M
Net Debt	950.77M	979.14M	861.37M	928.30M	931.88M	918.03M	903.99M	925.67M	879.16M	628.99M	676.61M	411.22M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-11-10Purchase

Owner: Kroll, Mark W

Title: -

Shares: 1,400

Price/Share: $70.56

Value: $98,784.00

Shares Owned: 24,757

Relationship: Director

Ownership: Direct

2024-07-26Sale

Owner: Strong, Stewart W

Title: President, Global Hospital

Shares: 4,312

Price/Share: $91.15

Value: $393,038.80

Shares Owned: 18,196

Relationship: Officer

Ownership: Direct

2024-07-12Sale

Owner: Lingamneni, Anila

Title: EVP, Chief Technology Officer

Shares: 79

Price/Share: $90.00

Value: $7,110.00

Shares Owned: 21,331

Relationship: Officer

Ownership: Direct

2024-05-29Sale

Owner: Strong, Stewart W

Title: President, Global Hospital

Shares: 8,857

Price/Share: $87.53

Value: $775,253.21

Shares Owned: 18,196

Relationship: Officer

Ownership: Direct

2024-05-29Sale

Owner: Basil, Michelle L

Title: EVP and General Counsel

Shares: 12,990

Price/Share: $88.22

Value: $1,145,977.80

Shares Owned: 31,257

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-11-10	Kroll, Mark W	Director	-	Direct	Purchase	1,400	70.56	$98,784.00	24,757	4
2024-07-26	Strong, Stewart W	Officer	President, Global Hospital	Direct	Sale	4,312	91.15	$393,038.80	18,196	4
2024-07-12	Lingamneni, Anila	Officer	EVP, Chief Technology Officer	Direct	Sale	79	90.00	$7,110.00	21,331	4
2024-05-29	Strong, Stewart W	Officer	President, Global Hospital	Direct	Sale	8,857	87.53	$775,253.21	18,196	4
2024-05-29	Basil, Michelle L	Officer	EVP and General Counsel	Direct	Sale	12,990	88.22	$1,145,977.80	31,257	4
2024-05-20	Llorens, Josep	Officer	EVP, Global Manufacturing	Direct	Sale	987	95.08	$93,843.96	21,310	4
2024-05-20	Strong, Stewart W	Officer	President, Global Hospital	Direct	Sale	686	95.11	$65,245.46	18,196	4
2024-05-20	Basil, Michelle L	Officer	EVP and General Counsel	Direct	Sale	1,604	95.08	$152,508.32	31,257	4
2024-05-16	Llorens, Josep	Officer	EVP, Global Manufacturing	Direct	Sale	770	96.14	$74,027.80	17,172	4
2024-05-16	Basil, Michelle L	Officer	EVP and General Counsel	Direct	Sale	985	96.14	$94,697.90	30,425	4
2024-05-16	Strong, Stewart W	Officer	President, Global Hospital	Direct	Sale	733	96.04	$70,397.32	15,608	4
2024-05-06	Lingamneni, Anila	Officer	EVP, Chief Technology Officer	Direct	Sale	2,305	95.00	$218,975.00	12,295	4
2023-09-12	Strong, Stewart W	Officer	President, Global Hospital	Direct	Sale	228	90.65	$20,668.20	16,221	4
2023-09-11	Lingamneni, Anila	Officer	EVP, Chief Technology Officer	Direct	Sale	2,305	90.00	$207,450.00	14,495	4
2023-09-05	Dockendorff, Charles J	Director	-	Direct	Sale	10,215	87.68	$895,651.20	2,226	4
2023-07-18	Llorens, Josep	Officer	EVP, Global Manufacturing	Direct	Sale	4,928	90.00	$443,520.00	18,463	4
2023-06-07	Strong, Stewart W	Officer	President, Global Hospital	Direct	Sale	2,538	88.04	$223,445.52	16,449	4
2023-05-30	Lingamneni, Anila	Officer	EVP, Chief Technology Officer	Direct	Sale	2,304	83.33	$191,992.32	16,800	4
2023-01-23	Llorens, Josep	Officer	EVP, Global Manufacturing	Direct	Sale	2,391	90.00	$215,190.00	17,234	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

96.33%

Inst. Shares: 45,448,704

Shares Outstanding: 47,179,000

2025-12-31

104.46%

Inst. Shares: 48,876,801

Shares Outstanding: 46,792,000

2025-09-30

103.92%

Inst. Shares: 49,453,484

Shares Outstanding: 47,590,000

2025-06-30

107.15%

Inst. Shares: 51,551,424

Shares Outstanding: 48,111,000

2025-03-31

99.96%

Inst. Shares: 50,311,739

Shares Outstanding: 50,330,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	45,448,704	47,179,000	96.33%
2025-12-31	48,876,801	46,792,000	104.46%
2025-09-30	49,453,484	47,590,000	103.92%
2025-06-30	51,551,424	48,111,000	107.15%
2025-03-31	50,311,739	50,330,000	99.96%
2024-12-31	51,752,461	50,286,000	102.92%
2024-09-30	50,140,560	50,898,000	98.51%
2024-06-30	52,139,946	50,943,000	102.35%
2024-03-31	47,961,015	50,706,000	94.59%
2023-12-31	48,192,948	50,768,000	94.93%
2023-09-30	48,119,900	50,727,000	94.86%
2023-06-30	47,543,222	50,542,000	94.07%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

HAEMONETICS CORP (HAE) — SEC Financial Statements & Analysis

HAEMONETICS CORP (HAE) is a surgical & medical instruments & apparatus company, incorporated in MA. HAEMONETICS CORP trades on NYSE as: HAE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), HAEMONETICS CORP reported a -0.96% year-over-year revenue growth, a Gross Profit Margin of 79.37% (TTM), a Debt-to-Equity ratio of 0.31x, a Price-to-Sales (P/S) ratio of 3.38x (TTM), a Price-to-Book (P/B) ratio of 4.06x (TTM), at a market cap of $3.40B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -0.96%
Gross Profit Margin TTM: 79.37%
Debt To Equity: 0.31x
P/S TTM: 3.38x
P/B TTM: 4.06x
Market Cap: $3.40B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is HAEMONETICS CORP in?

HAEMONETICS CORP (HAE) operates in the Surgical & Medical Instruments & Apparatus industry.

What is HAE's market cap?

HAEMONETICS CORP (HAE) has a market capitalization of $3.40B as of 2026-06-30.

What is HAE's P/E ratio?

HAEMONETICS CORP (HAE)'s trailing twelve month P/E ratio is 35.33x as of 2026-06-30.

What exchange does HAE trade on?

HAEMONETICS CORP (HAE) trades on the NYSE.

Where is HAEMONETICS CORP incorporated?

HAEMONETICS CORP is incorporated in MA.